Received Mar 11, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | UNK | — |
Flu; This non-serious case was reported by a consumer via call center representative and described the occurrence of influenza in a female patient who received Men B NVS (Bexsero) for prophylaxis. In NOV-2025, the patient received the 1st dose of Bexsero. On an unknown date, an unknown time after receiving Bexsero, the patient experienced influenza (Verbatim: Flu). The outcome of the influenza was unknown. It was unknown if the reporter considered the influenza to be related to Bexsero and Bexsero Pre-Filled Syringe Device. It was unknown if the company considered the influenza to be related to Bexsero and Bexsero Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date 27-FEB-2026 The patient received one dose of BEXSERO and instructions from the hospital advised her to have the second dose injected in one month. The patient stated the instructions were for the two dose schedule. The patient reported she had not had the second dose of Bexsero administered because she had the flu. The patient reported the information provided by the hospital was confusing. No further information was provided.